3CPM Company

CURING THE INCURABLE
ABOUT THE COMPANYBOARD OF DIRECTORS

ABOUT THE 3CPM Company®

3CPM Company was formed in January 1998 to promote and further the proprietary Electrogastrogram (EGG) technology developed by one of its founders, Kenneth Koch, MD, and to capitalize on the resulting market opportunity.

Dr. Koch is the Section Head of Section on Gastroenterology at Wake Forest University. As a world-renowned expert in diagnostic gastroenterology, Dr. Koch developed the initial EGG and associated EGGSAS software for clinical use. The 3CPM® device detects, records, and analyzes the electrical activity of the stomach to diagnose the gastric myoelectrical activity (GMA) and abnormalities in a quick, accurate, and reproducible manner.

These detected abnormalities are associated with a number of conditions that afflict millions worldwide. 3CPM® is fortunate to have one of the world’s leading experts in this emerging field as a founder, director and officer of the Company. 3CPM was co-founded in 1998 by a seasoned medical device President/CEO and a CFO, both of whom had had several successful start ups to their credit. In 2001, 3CPM brought Mark D. Noar, MD, an established user and recognized gastroenterologist, onto the board.

 

ABOUT THE 3CPM Company®

Company was formed in January 1998 to promote and further the proprietary Electrogastrogram (EGG) technology developed by one of its founders, Kenneth Koch, MD, and to capitalize on the resulting market opportunity.

Dr. Koch is the Section Head of Section on Gastroenterology at Wake Forest University. As a world-renowned expert in diagnostic gastroenterology, Dr. Koch developed the initial EGG and associated EGGSAS software for clinical use. The 3CPM® device detects, records, and analyzes the electrical activity of the stomach to diagnose the gastric myoelectrical activity (GMA) and abnormalities in a quick, accurate, and reproducible manner.

These detected abnormalities are associated with a number of conditions that afflict millions worldwide. 3CPM® is fortunate to have one of the world’s leading experts in this emerging field as a founder, director and officer of the Company. 3CPM was co-founded in 1998 by a seasoned medical device President/CEO and a CFO, both of whom had had several successful start ups to their credit. In 2001, 3CPM brought Mark D. Noar, MD, an established user and recognized gastroenterologist, onto the board.

 

The Invention Of The Device

This noninvasive, user-friendly system was developed and tested on over 1,000 patients presenting with difficult symptomatology and also in animal drug research. The device’s validity and reliability liken its potential to the extensively-used electrocardiogram (EKG). After testing, 3CPM obtained regulatory clearance from the FDA in 1998, then US patent and copyright protection. The initial US-based product launch further defined the following clinical categories: tachygastria, bradygastria, and reflux-related GERD+ Dyspepsia, which affects millions more in the population than previously identified. The incorporation of population-based normal values, against which disease states may be distinguished, is what makes 3CPM’s EGG unique. No other device in the field is able to make this claim.

The Invention Of The Device

This noninvasive, user-friendly system was developed and tested on over 1,000 patients presenting with difficult symptomatology and also in animal drug research. The device’s validity and reliability liken its potential to the extensively-used electrocardiogram (EKG). After testing, 3CPM obtained regulatory clearance from the FDA in 1998, then US patent and copyright protection. The initial US-based product launch further defined the following clinical categories: tachygastria, bradygastria, and reflux-related GERD+ Dyspepsia, which affects millions more in the population than previously identified. The incorporation of population-based normal values, against which disease states may be distinguished, is what makes 3CPM’s EGG unique. No other device in the field is able to make this claim.

The most recent developments for 3CPM’s EGG include:

• the creation of new predictive conformational statistical diagnostic methodologies, based upon the strength and reproducibility of the 3cpm (3 cycles per minute) signal, and…

• the disease-related threshold software, known as the EGG GMAT®, which defines both specific gastroparesis subtypes and the predictability of therapy’s success for this disease.

MORE ABOUT THE 3CPM

Dr. Noar was appointed Board Chairman and CEO. Under his guidance, 3CPM has continued to advance and mature with the development of:

• research-specific software platforms for animal and human research,

• software tools to allow automatic detection and correction of hardware and software errors,

• companion software programs to facilitate device use in large research-based projects with the National Institutes of Health (NIH) and the pharmaceutical industry,

• additional US and worldwide patents and IP protection, and

• successful entry into large international markets including Korea and China.

In collaboration with Dr. Koch, further advances in hardware development led to the creation of novel endoscopic tools. These tools allow EGG technology to be introduced endoscopically in order to directly diagnose and treat gastric motility disorders.3CPM® Company’s present board is the core management team necessary to grow and build the Company.

The current board (5/5 seats filled) has an impressive range of relevant experiences, which has enhanced its ability to quickly accomplish the business plan’s objectives.

The most recent developments for 3CPM’s EGG include:

• the creation of new predictive conformational statistical diagnostic methodologies, based upon the strength and reproducibility of the 3cpm (3 cycles per minute) signal, and…

• the disease-related threshold software, known as the EGG GMAT®, which defines both specific gastroparesis subtypes and the predictability of therapy’s success for this disease.

MORE ABOUT THE 3CPM

Dr. Noar was appointed Board Chairman and CEO. Under his guidance, 3CPM has continued to advance and mature with the development of:

• research-specific software platforms for animal and human research,

• software tools to allow automatic detection and correction of hardware and software errors,

• companion software programs to facilitate device use in large research-based projects with the National Institutes of Health (NIH) and the pharmaceutical industry,

• additional US and worldwide patents and IP protection, and

• successful entry into large international markets including Korea and China.

In collaboration with Dr. Koch, further advances in hardware development led to the creation of novel endoscopic tools. These tools allow EGG technology to be introduced endoscopically in order to directly diagnose and treat gastric motility disorders.3CPM® Company’s present board is the core management team necessary to grow and build the Company.

The current board (5/5 seats filled) has an impressive range of relevant experiences, which has enhanced its ability to quickly accomplish the business plan’s objectives.

The Board of Directors

The 3CPM Company was formed in January 1998 to exploit the proprietary Electrogastrogram (EGG) technology developed by one of its founders, Kenneth Koch, MD, and to capitalize on the resulting market opportunity.

Dr. Mark Noar

Dr. Mark Noar

Chairman, CEO and Director

Noar is a private practice gastroenterologist, with a large clinic in Towson, MD. He has conducted a number of clinical research projects, including the ability of EGG to screen and predict success with surgical intervention for GERD patients. He has published extensively and is an acknowledged expert in reimbursement matters for private practice. He is an advisor to the pharmaceutical and medical device industries, with a successful history of technology introduction and evaluation. Since joining the company he has overseen the development and patent of the newer version of the EGG, integrating computer-based interpretation and diagnostics into the field and the latest open architecture Research focused EGG, selected as the exclusive EGG used by the NIH in their sponsored research.

Dr. Kenneth Koch

Dr. Kenneth Koch

Co-Founder

Dr. Koch is the Section Head of Section on Gastroenterology at Wake Forest University. As a world-renowned expert in diagnostic gastroenterology, Dr. Koch developed the initial EGG and associated EGGSAS software for clinical use. 

3CPM® is fortunate to have one of the world’s leading experts in this emerging field as a founder, director and officer of the Company.  In 2001, 3CPM brought Mark D. Noar, MD, an established user and recognized gastroenterologist, onto the board.

Bernie DiDario

Bernie DiDario

Director and Co-Founder

From 1984 to 1990 he was the President of Industrial Fermentation Genetics, a biotech Company which manufactured and sold specialty proteins derived from genetic engineering. The Company was acquired in 1990. From 1982 to 1984 he was the President of California Integrated Diagnostics, a manufacturer of kits for the detection of sexually transmitted diseases. The Company was acquired in 1984 by a larger competitor. He was also a senior consultant with Arthur D. Little, Inc. and was involved with strategic and marketing assignments with numerous companies in the medical area. Mr. DiDario currently serves on the Board of three companies with a technology focus and products for the financial services and RFID/GPS asset tracking markets.

Wendell W. Jones II

Wendell W. Jones II

Director

Since 2008 Mr. Jones is “The Serial CFO” where he provides interim and consulting CFO services to a number of embryonic Companies in Silicon  Valley including a laser manufacturer, a medical device company, and several small businesses which require finance and/or accounting advice. From 2004 through 2008, he was a Director for the CPA firm Louie and Wong. From 1997 through 2004, he was the CFO of 3CPM through 2004. Prior to that he was the CFO for Maven Labs, Inc. from 1992 to 1997, where he was responsible for finance, accounting, investor relations, treasury and information systems functions. From 1990 to 1992, he was a consultant to the Chairman of Network Solutions, Inc., a Company that engaged in the exclusive registration of Internet addresses. Mr. Jones is also Board Chair for Main Street Launch.

Mr. Carlos Babini

Mr. Carlos Babini

Chief Commercialization Officer and Senior Vice President of SurgiQuest, Inc. a private, start-up medical device company where he helped build revenue to 50 Million Dollars prior to its acquisition earlier part of 2016 by CONMED Corporation (CNMD) for 265 Million US Dollars.Carlos Babini, joined SurgiQuest in 2008, as an accomplished senior executive with more than 25 years of key leadership experience in sales, marketing, strategic development and commercialization initiatives in highly competitive sectors of both the capital and non-capital medical device industry.

During his 20 year career at U.S. Surgical Corporation he helped build sales revenue to 1.3 Billion US Dollars prior to the sale of USSC to Tyco Healthcare, later known as Covidien (now Medtronic) for 3.9 Billion US Dollars. Mr. Babini is globally recognized for building high performance, extremely disciplined, customer focused world-class teams and for facilitating organizational high standards of excellence.

The Board of Directors

The 3CPM Company was formed in January 1998 to exploit the proprietary Electrogastrogram (EGG) technology developed by one of its founders, Kenneth Koch, MD, and to capitalize on the resulting market opportunity.

Dr. Mark Noar

Dr. Mark Noar

Chairman, CEO and Director

Noar is a private practice gastroenterologist, with a large clinic in Towson, MD. He has conducted a number of clinical research projects, including the ability of EGG to screen and predict success with surgical intervention for GERD patients. He has published extensively and is an acknowledged expert in reimbursement matters for private practice. He is an advisor to the pharmaceutical and medical device industries, with a successful history of technology introduction and evaluation. Since joining the company he has overseen the development and patent of the newer version of the EGG, integrating computer-based interpretation and diagnostics into the field and the latest open architecture Research focused EGG, selected as the exclusive EGG used by the NIH in their sponsored research.

Dr. Kenneth Koch

Dr. Kenneth Koch

Co-Founder

Dr. Koch is the Section Head of Section on Gastroenterology at Wake Forest University. As a world-renowned expert in diagnostic gastroenterology, Dr. Koch developed the initial EGG and associated EGGSAS software for clinical use. 

3CPM® is fortunate to have one of the world’s leading experts in this emerging field as a founder, director and officer of the Company.  In 2001, 3CPM brought Mark D. Noar, MD, an established user and recognized gastroenterologist, onto the board.

Bernie DiDario

Bernie DiDario

Director and Co-Founder

From 1984 to 1990 he was the President of Industrial Fermentation Genetics, a biotech Company which manufactured and sold specialty proteins derived from genetic engineering. The Company was acquired in 1990. From 1982 to 1984 he was the President of California Integrated Diagnostics, a manufacturer of kits for the detection of sexually transmitted diseases. The Company was acquired in 1984 by a larger competitor. He was also a senior consultant with Arthur D. Little, Inc. and was involved with strategic and marketing assignments with numerous companies in the medical area. Mr. DiDario currently serves on the Board of three companies with a technology focus and products for the financial services and RFID/GPS asset tracking markets.

Wendell W. Jones II

Wendell W. Jones II

Director

Since 2008 Mr. Jones is “The Serial CFO” where he provides interim and consulting CFO services to a number of embryonic Companies in Silicon  Valley including a laser manufacturer, a medical device company, and several small businesses which require finance and/or accounting advice. From 2004 through 2008, he was a Director for the CPA firm Louie and Wong. From 1997 through 2004, he was the CFO of 3CPM through 2004. Prior to that he was the CFO for Maven Labs, Inc. from 1992 to 1997, where he was responsible for finance, accounting, investor relations, treasury and information systems functions. From 1990 to 1992, he was a consultant to the Chairman of Network Solutions, Inc., a Company that engaged in the exclusive registration of Internet addresses. Mr. Jones is also Board Chair for Main Street Launch.

Mr. Carlos Babini

Mr. Carlos Babini

Chief Commercialization Officer and Senior Vice President of SurgiQuest, Inc. a private, start-up medical device company where he helped build revenue to 50 Million Dollars prior to its acquisition earlier part of 2016 by CONMED Corporation (CNMD) for 265 Million US Dollars.Carlos Babini, joined SurgiQuest in 2008, as an accomplished senior executive with more than 25 years of key leadership experience in sales, marketing, strategic development and commercialization initiatives in highly competitive sectors of both the capital and non-capital medical device industry.

During his 20 year career at U.S. Surgical Corporation he helped build sales revenue to 1.3 Billion US Dollars prior to the sale of USSC to Tyco Healthcare, later known as Covidien (now Medtronic) for 3.9 Billion US Dollars. Mr. Babini is globally recognized for building high performance, extremely disciplined, customer focused world-class teams and for facilitating organizational high standards of excellence.

3CPM Office

Location

7402 York Rd, Ste 100 Towson MD 21204

(+1) 410-494-1846

info@3cpm.com

Get In Touch

Have a question? Intersted in having an EGG for your Endoscopy center? Feel free to contact us below.